PhRMA: The biopharmaceutical industry is committed to improving the benefits of cancer patients, with more than 1,100 potentially innovative drugs under development

PhRMA has released a report on cancer drug development.
PhRMA: The biopharmaceutical industry is committed to improving the benefits of cancer patients, more than 1,100 potentially innovative drugs are under development October 26, 2020, Beijing - The American Association of Pharmaceutical Research and Manufacturers (PhRMA) recently released a report on cancer drug development, highlighting the biopharmaceutical industry's commitment to fighting the epidemic while continuing to fight cancer, and continue to achieve new cancer research results in a critical clinical environment.
the report explores setbacks in drug development, but also recognizes that failure can translate into experience and knowledge and continue to drive future research.
biopharmaceutical industry is currently developing more than 1,100 potential cancer drugs and is committed to transforming cancer from a deadly disease to a controlled chronic disease.
report show the setbacks and challenges that must be encountered in this process, as well as the progress and breakthroughs represented by new therapies after years of research and setbacks.
is an inevitable part of the research process," said Stephen J. Ubl, President and CEO of PhRMA.
but scientists can gain experience from setbacks and gain knowledge and information that will contribute to future innovative drug development, including new treatments and potential combinations of treatments.
", based on data from the U.S. Food and Drug Administration, the report analyzed the approval of nine different cancer drugs and showed that the cancer drug research process was challenging: 158 drugs failed, 12 approved brain cancers: 122 drugs failed. 3 approved, acute myeloid leukemia: 91 drug failures, 7 approved kidney cancers: 96 drug failures, 11 approved liver cancers: 73 drug failures 5 approved lung cancer: 268 drug failures, 32 approved pancreatic cancers: 131 drug failures, 7 approved ovarian cancers: 139 drug failures, 13 Approved prostate cancer: 237 drugs failed and 21 were approved in the United States, and cancer deaths have fallen by 29% since peaking in 1991, meaning that at least 2.9 million people have been prevented from dying from cancer.
the latest figures, the death rate fell by 2.2 per cent between 2016 and 2017 alone, the biggest one-year drop on record.
, the five-year relative survival rate of cancer has also steadily increased.
from 2003 to 2015, survival rates jumped from 30.9 per cent to 40.5 per cent.
China is committed to continuing this upward trend, with the goal of increasing its survival rate to 43.3% and 46.6% respectively by 2022 and 2030.
innovation in cancer therapy can reduce cancer deaths and play an important role in achieving this goal.
reforms in China have made great sleer progress in reaching cancer patients.
China has eliminated import tariffs on cancer drugs since 2018, and in 2019, Health China action highlights cancer prevention and treatment.
, China's State Drug Administration has also achieved important results in speeding up the review and approval of cancer drugs.
2019, the National Drug Administration approved 58 innovative drugs (including new adaptations) from the global biopharmaceutical industry, including 20 cancer-related adaptations.
the first half of 2020, the Center has approved 27 new drugs, seven of which are linked to cancer treatment.
China's National Health Insurance Drug Catalog (NRDL) continues to evolve and make more dynamic adjustments to provide patients with more innovative oncology drugs.
cancer drugs accounted for 23% of all drugs in NRDL in 2019.
This year, the biopharmaceutical industry saw China's commitment to further improving patient access and a more open attitude , with adjustments allowing more innovative oncology and adaptive applications to enter the list of medicare drugs, dramatically reducing the time it takes for drugs to be marketed in China to patients.
many new cancer treatments are bringing hope to cancer patients in China and around the world.
"Ubl further stated, "These advances and successes are the result of collaboration across the scientific community and are inextricable to the important contributions made by patients involved in clinical trials."
"